New Generic Equivalent for Lutera® 28 / by TI

Amneal adds Larissia™ to its growing line of women’s health products

Bridgewater, NJ (USA), June 29, 2016 – Amneal Pharmaceuticals LLC (“Amneal”) today announced the launch of its AB-rated generic for Lutera® 28 (levonorgestrel and ethinyl estradiol tablets, USP) 0.1 mg/0.02 mg, the reference listed drug for the former Alesse® brand. The Amneal generic will be sold under the trade name Larissia™ for ease of reference.   
Larissia™ joins four other women’s health products (including oral contraceptives and hormone replacement therapies) in the Amneal product line. Several other products are planned for launch before year-end, further strengthening the company’s growing women’s health line.  
“Our women’s health product pipeline is rich with complex formulations, new dosage forms and devices dedicated to addressing specific women’s health concerns,” explains Jim Luce, executive vice president of sales & marketing for Amneal. “We are committed to expanding this category beyond 2016 and continuing to deliver high quality products and service to this patient population and its healthcare providers.”   
Levonorgestrel and ethinyl estradiol tablets, USP 0.1 mg/0.02 mg was first approved by the FDA in March 1997 under the brand name, Alesse®.  According to March 2016 IMS market data, annual U.S. sales for this product totaled $217.4 million.  
Please click here to see the full prescribing information for Larissia™.
About Amneal Pharmaceuticals LLC
Amneal Pharmaceuticals LLC is a global supplier of generic pharmaceuticals, verticallyintegrated across the entire supply chain from R&D to finished goods. Since its inception in 2002, Amneal has invested extensively in R&D resources, manufacturing infrastructure, and strategic expansion opportunities—all contributing to its significant growth. The Company prides itself on its unwavering commitment to quality, strong business relationships, and innovative approach to maximizing value. Amneal is privately-held with U.S. headquarters in Bridgewater, New Jersey and international headquarters in Zug, Switzerland.  For more information, please visit
All trademarks listed in this release are property of their respective owners.

Jim Luce (sales) Executive Vice President, Sales & Marketing
M:   949.500.5756    
Apurva Saraf (investors) Vice President, Global Strategy & Development D : 908.947.3740  
Laurene Isip (media) Senior Director, Corporate Communications D : 908 409 6819